A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution (2.5 mcg and 5 mcg) Delivered Via Respimat Inhaler Once Daily in the Evening Over 48 Weeks in Children (6 to 11 Years Old) With Moderate Persistent Asthma

Trial Profile

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution (2.5 mcg and 5 mcg) Delivered Via Respimat Inhaler Once Daily in the Evening Over 48 Weeks in Children (6 to 11 Years Old) With Moderate Persistent Asthma

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Mar 2018

At a glance

  • Drugs Tiotropium bromide (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms CanoTinA-asthma
  • Sponsors Boehringer Ingelheim Pharmaceuticals; Unilfarma
  • Most Recent Events

    • 16 Mar 2018 According to a Boehringer Ingelheim media release, the regulatory authorities in the EU have accepted an expanded indication for SPIRIVA Respimat (tiotropium Respimat) add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations. The approval was supported by extensive data from the UniTinA-asthma trial program.
    • 24 May 2017 Results of pooled data analysis of 10 phase III studies (NinoTinA-asthma, CanoTinA-asthma,VivaTinA-asthma, RubaTinA-asthma,PensieTinA-asthma,GraziaTinA-asthma,MezzoTinA-asthma,PrimoTinA-asthma) assessing safety and tolerability presented at the 113th International Conference of the American Thoracic Society.
    • 24 May 2017 Results of pooled analysis from two phase III studies, presented at the 113th International Conference of the American Thoracic Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top